Core Insights - QHSLab Inc. reported strong financial results for Q1 2025, with total revenue increasing by 32.1% year-over-year to $645,419, driven by growth in Integrated Service Program (ISP) and Allergy Diagnostics [2][6][7] - The company achieved a gross profit of $429,944, up from $286,158 in the prior-year period, with gross margin expanding to 66.6% from 58.6% in Q1 2024, reflecting improved product mix and operational efficiencies [6][7] - CEO Troy Grogan emphasized the structural advantages of the company's diversified revenue model and the focus on sustainable margin expansion and shareholder value [2][6] Financial Highlights - Revenue Breakdown for Q1 2025: - Allergy Diagnostics: $264,913, up 11.7% from $237,066 in Q1 2024 - ISP Services: $162,502, up 28.0% from $127,004 in Q1 2024 - Immunotherapy: $97,329, up 12.8% from $86,325 in Q1 2024 - Clinical Study: $89,100, new revenue stream - Subscriptions: $9,285, down 49.5% from $18,370 in Q1 2024 - Shipping & Handling: $9,970, stable compared to $9,959 in Q1 2024 - Training & Other: $12,320, up 24.9% from $9,863 in Q1 2024 [2][6][7] Company Overview - QHSLab Inc. is a digital health company focused on personalized medicine through innovative population health screening and point-of-care diagnostic tools for primary care [1][4] - The company utilizes advanced artificial intelligence algorithms to enhance patient monitoring and medical care, aiming to improve healthcare outcomes while increasing revenue for physicians [4]